BioSpace News Archive

Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.

Panbela today announced an Issue Notification for the Chinese patent 201980010826.7 titled “METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL”.

Today COTA announced Vista, a large-scale automated electronic health record (EHR) dataset to accelerate cancer research and the deployment of trusted generative AI in cancer care.

Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”) and Nephron Pharmaceuticals Corporation, (“Nephron”) a privately owned U.S. leader in contract manufacturing and 503B outsourcing, announce the signing of an Asset Purchase Agreement (APA) to acquire Nephron’s InjectEZ specialty syringe manufacturing facility.

Galmed Pharmaceuticals Ltd. announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis.

ValGenesis, Inc. and Astrix, a digital transformation and specialized services company, have partnered to provide regulatory advisory and validation services alongside the ValGenesis product suite for life sciences companies across North America.

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that data from its LIVMARLI ® (maralixibat) oral solution studies as well as data from real- world experience will be presented at the upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) annual meeting taking place October 4-7, 2023, in San Diego, California.

Blue Earth Diagnostics today announced that its optimized radiohybrid (rh) Prostate-Specific Membrane Antigen (PSMA)-targeted PET imaging agent, POSLUMA® (flotufolastat F 18) injection (formerly referred to as 18F-rhPSMA-7.3), has been granted Transitional Pass-Through payment status for diagnostic radiopharmaceutical reimbursement by the Centers for Medicare & Medicaid Services (CMS), effective October 1, 2023.

Mirvie has been certified by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity clinical testing.

Carmot Therapeutics Inc. today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany.